Navigation Links
In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
Date:8/5/2010

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection (CDI), nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

The new Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members finds that fidaxomicin and, to a higher degree, CDA1/CDB1, will also see robust uptake by surveyed clinicians for the treatment of recurrent CDI. The report also finds that approximately two-thirds of pharmacy and therapeutics committee (P&T) members expect to include fidaxomicin and CDA1/CDB1 on their hospital's formulary.

Fidaxomicin and CDA1/CDB1 would provide much needed options for the treatment of CDI as the only currently available agents in this indication are Pfizer's metronidazole (generically available) and ViroPharma's Vancocin. According to the report, unmet need for novel anti-infectives is shifting away from methicillin-resistant Staphylococcus aureus (MRSA) to CDI and gram-negative infections.

"In addition to MRSA, infectious disease specialists report a rise in CDI and gram-negative infections," said Decision Resources Therapeutic Area Director Danielle Drayton, Ph.D. "Over the past 12 months, 82 percent of surveyed infectious disease specialists observed an increase in the incidence of ESBL-producing enterobacteriaceae while more than half of surveyed clinicians also point to an increase in the incidence of CDI and MRSA. Drugs that target key gram-negative pathogens such as Pseudomonas aeruginosa and ESBL-producing enterobacteriaceae and Clostridium difficile stand to address a key unmet need and will capitalize on untapped market opportunities."

The report also finds that Forest/AstraZeneca/Takeda's ceftaroline and Trius's torezolid are the two late-stage emerging therapies that are most likely to gain formulary inclusion, according to surveyed P&T committee members. Seventy one percent of surveyed P&T committee members expect torezolid to be on formulary and 62 percent expect ceftaroline to be on formulary.

Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members is based on a U.S. survey of 51 infectious disease specialists, 52 internal medicine specialists and 21 infectious disease specialists who sit on their hospital's P&T committee.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. WuXi PharmaTech Announces First-Quarter 2010 Results
3. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
4. Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. VELOCITY Broadcasting Introduces HD2PC(SM), the First-Ever High-Definition Direct to PC Delivery of Private Broadcast Television
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
9. Lilly Declares First-Quarter 2010 Dividend
10. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
11. CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):